Cargando…

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies

Purpose: Immune checkpoint and antiangiogenic inhibitors have a potentially synergistic antitumor effect. We aimed to assess the efficacy and safety of immunotherapy in combination with antiangiogenesis therapy with or without chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Ruo-Lin, Song, Jun, Sun, Li, Wu, Zhi-Xuan, Yi, Xiao-Fang, Zhang, Shu-Ling, Huang, Le-Tian, Ma, Jie-Tao, Han, Cheng-Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399640/ https://www.ncbi.nlm.nih.gov/pubmed/36034821 http://dx.doi.org/10.3389/fphar.2022.920165

Ejemplares similares

Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy
por: Wan, Xueting, et al.
Publicado: (2021)

Computational Prediction of Antiangiogenesis Synergistic Mechanisms of Total Saponins of Panax japonicus Against Rheumatoid Arthritis
por: Guo, Xiang, et al.
Publicado: (2020)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing
por: Jiang, Man, et al.
Publicado: (2021)

Dual sEH/COX-2 Inhibition Using PTUPB—A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity
por: Jankiewicz, Wojciech K., et al.
Publicado: (2021)

Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis
por: Wang, Ji, et al.
Publicado: (2016)

Monitoring antiangiogenesis of bevacizumab in zebrafish
por: Zhang, Jing, et al.
Publicado: (2018)

Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma
por: Xia, Qin-Xuan, et al.
Publicado: (2022)

Surrogate markers in antiangiogenesis clinical trials
por: Davis, D W, et al.
Publicado: (2003)

Antiangiogenesis in recurrent glioblastoma: proof of principle
por: Nossek, Erez, et al.
Publicado: (2009)

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
por: Li, Song, et al.
Publicado: (2023)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
por: Cheng, Chunliang, et al.
Publicado: (2021)

Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies
por: Lasalvia-Prisco, Eduardo, et al.
Publicado: (2012)

Antiangiogenesis therapy: an update after the first decade
por: De Falco, Sandro
Publicado: (2014)

Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer
por: Wu, Li Cun, et al.
Publicado: (2008)

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer()
por: Ribatti, Domenico, et al.
Publicado: (2016)

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors
por: Touyz, Rhian M., et al.
Publicado: (2019)

Safety profile of intravenous digoxin in Chinese patients with acute heart failure with reduced ejection fraction: a small-scale prospective cohort study
por: Liu, Xintian, et al.
Publicado: (2023)

Efficacy and safety of weekly versus triweekly cisplatin treatment concomitant with radiotherapy for locally advanced nasopharyngeal carcinoma: A systematic review and pooled analysis
por: Tian, Xin, et al.
Publicado: (2023)

Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma
por: Zheng, Yang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China
por: Zhu, Chen, et al.
Publicado: (2021)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

Editorial: Chemosensitizing effect of natural products against cancers: Applications in enhancing chemotherapy and immunotherapy
por: Roy, Nand K., et al.
Publicado: (2022)

Isthmin inhibits glioma growth through antiangiogenesis in vivo
por: Yuan, Bangqing, et al.
Publicado: (2012)

From antiangiogenesis to hypoxia: current research and future directions
por: Rice, Christopher, et al.
Publicado: (2010)

Emerging roles for antiangiogenesis factors in management of ocular disease
por: Saeed, Muhammad Usman, et al.
Publicado: (2013)

Antiangiogenesis and antioxidant activity of ethanol extracts of Pithecellobium jiringa
por: Muslim, Nahdzatul Syima, et al.
Publicado: (2012)

Cavity development: a potential biomarker for antiangiogenesis agents
por: Jiang, Man, et al.
Publicado: (2020)

Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: A prospective cohort study
por: Gebreyesus, Tigist Dires, et al.
Publicado: (2023)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Comprehensive Analysis of Necroptosis in Pancreatic Cancer for Appealing its Implications in Prognosis, Immunotherapy, and Chemotherapy Responses
por: Fang, Kun, et al.
Publicado: (2022)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
por: Li, Huixia, et al.
Publicado: (2023)

Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: Two case reports
por: Zhou, Daibing, et al.
Publicado: (2021)

Efficacy of first-line immunization combined with antiangiogenesis treatment and chemotherapy for the treatment of tongue cancer: A case report
por: Zhao, Limin, et al.
Publicado: (2023)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
por: Xie, Renxian, et al.
Publicado: (2023)

Immunotherapy strategies and prospects for acute lung injury: Focus on immune cells and cytokines
por: Zhu, Wenfang, et al.
Publicado: (2022)

Nucleolin mediates the antiangiogenesis effect of the pseudopeptide N6L
por: Birmpas, Charalampos, et al.
Publicado: (2012)

The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis
por: Ribatti, Domenico
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7la90ke4d3u8728ln2ptojtfdg